Precigen reports pipeline progress and R&D Day for PRGN-2012 data on Jan 24, 2023

PRECIGEN, INC.

PRGN-2012 Phase 2 enrollment rapid; 20 patients enrolled; R&D Day Jan 24 to share Phase 1 data.
PRGN-2009 Phase 2 monotherapy arm near full enrollment: 19 of 20 patients; interim data expected H2 2023.
PRGN-3006 in AML: Phase 1 dose escalation data presented at ASH; Phase 1b expansion includes Mayo Clinic; first repeat dose cleared.
PRGN-3005 in ovarian cancer: Phase 1 dose escalation completed; first repeat dose given; expansion enrollment ongoing.
PRGN-3007 (next-gen UltraCAR-T) trial open for enrollment; first patient dosing expected Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.